Treatment of Hyperlipidemia: Consensus and Controversies
Based on epidemiological, genetic, and clinical trial data, there is a consensus now that low-density lipoproteins (LDL) cholesterol causes atherosclerosis and that lowering LDL cholesterol reduces the risk of atherosclerotic cardiovascular disease. Current guidelines on lipid management, therefore,...
Main Authors: | Christoph H Saely, Reinhard R Saely, Heinz Drexel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
Series: | Cardiology Plus |
Subjects: | |
Online Access: | http://www.cardiologyplus.org/article.asp?issn=2470-7511;year=2017;volume=2;issue=4;spage=18;epage=25;aulast=Saely |
Similar Items
-
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
by: Frederick J. Raal, et al.
Published: (2016-06-01) -
Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts
by: Shamanna S Iyengar
Published: (2016-01-01) -
Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol
by: Moumita Ghosh, et al.
Published: (2015-02-01) -
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01) -
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
by: Hua Sun, et al.
Published: (2018-02-01)